Twist Bioscience (TWST) Cash & Equivalents (2018 - 2026)

Twist Bioscience has disclosed Cash & Equivalents across 9 years of filings, most recently posting $122.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 41.69% year-over-year to $122.7 million; the TTM figure through Mar 2026 stood at $122.7 million (down 41.69% YoY), while the FY2025 annual figure was $183.0 million, down 19.12% from the prior year.
• Cash & Equivalents fell to $122.7 million in Q1 2026, from $148.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for TWST reached as high as $407.6 million in Q1 2022 and fell as low as $122.7 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $243.3 million (2024), against an average of $261.8 million.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 65.26% — and 2026, when it plunged 41.69%.
• A 5-year view of Cash & Equivalents shows it stood at $316.7 million in 2022, then dropped by 15.92% to $266.3 million in 2023, then slipped by 16.85% to $221.4 million in 2024, then tumbled by 32.88% to $148.6 million in 2025, then declined by 17.43% to $122.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $122.7 million, $148.6 million, and $183.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.